USPTO serial 87417104
Serial No. 87417104
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 24, 2018
- Examiner
- SEVERSON, KAREN
- Law office
- Historical data usage
What this means
Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.
Need help with Serial No. 87417104?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kisuk Lee
Kisuk Lee Harness, Dickey & Pierce, PLC7700 Bonhomme Avenue, Suite 400Saint Louis, MO 63105United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Vaccines; medicines for sensory organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of sensory organ; agents affecting peripheral nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the peripheral nervous system; agents for immunity adjustment, namely, pharmaceutical preparations for the prevention and treatment of disorders of the immune system; biological preparations for medical purposes; amino acids for medical purposes; antibiotic preparations; agents for respiratory organs, namely, pharmaceutical preparations for the prevention and treatment of disorders of respiratory organs; chemotherapeutics; reagents for measuring Hepatitis B Surface antibody, namely, medical diagnostic reagents for detecting Hepatitis B surface antibody; diagnostic preparations for medical use; AIDS, acquired immune deficiency syndrome diagnostic agents, namely, diagnostic preparation for medical use; AIDS, acquired immune deficiency syndrome vaccines; agents affecting central nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the nervous system; veterinary vaccines; agents for tumor treatment, namely, pharmaceutical preparations for the treatment of tumor; agents for urogenital organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of urogenital organs; kits for protein test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a protein related to a disease; kits for gene test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a gene related to a disease; biopharmaceuticals for the treatment and prevention of infectious diseases, tumor- related diseases, auto-immune diseases, hormone- deficiency diseases; biopharmaceutical preparations, namely, polypeptides, proteins, monoclonal antibodies, hormones for the treatment and prevention of infectious diseases, tumor-related diseases, auto-immune diseases, hormone deficiency diseases; biotherapeutic preparations and substances for medical purposes for the treatment of rheumatoid arthritis, cancer, inflammations, transplant rejection, autoimmune diseases, autoimmune disorders, infectious diseases; biotechnological preparations for medical purposes for the treatment of rheumatoid arthritis, cancer, inflammations, transplant rejection, autoimmune diseases, autoimmune disorders, infectious diseases; pharmaceuticals for the treatment of rheumatoid arthritis, cancer, inflammations, transplant rejection, autoimmune diseases, autoimmune disorders, infectious diseases, tuberculosis, HIV/AIDS, neurological disorders, urge incontinence, neurogenic detrusor overactivity; chemical preparations for pharmaceutical purposes, namely, chemical reagents for medical purposes; chemico-pharmaceutical preparations for the treatment of tuberculosis, HIV/AIDS, neurological disorders, urge incontinence, neurogenic detrusor overactivity | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 13, 2024 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Dec 13, 2024 | 8.OK | REGISTERED - SEC. 8 (6-YR) ACCEPTED | The USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline. |
| Dec 13, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 28, 2024 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Apr 24, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 26, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 24, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 6, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 6, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 17, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 28, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 7, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 7, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 7, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 14, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 14, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 14, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 12, 2017 | DMCC | DATA MODIFICATION COMPLETED | — |
| Jun 12, 2017 | ALIE | ASSIGNED TO LIE | — |
| Jun 8, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 26, 2017 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Apr 25, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 22, 2017 | NWAP | NEW APPLICATION ENTERED | — |